Biofrontera (BFRI) EBITDA (2020 - 2025)

Biofrontera's EBITDA history runs 6 years deep, the most recent figure standing at $4.6 million for Q4 2025.

• On a quarterly basis, EBITDA rose 366.3% year-over-year to $4.6 million in Q4 2025; TTM through Dec 2025 was -$11.3 million, a 34.08% increase from a year earlier, with the FY2025 full-year figure at -$11.3 million, up 34.06% from the prior year.
• EBITDA rose to $4.6 million in Q4 2025 per BFRI's latest filing, from -$6.3 million in the prior quarter.
• Across five years, EBITDA topped out at $4.6 million in Q4 2025 and bottomed at -$16.1 million in Q3 2021.
• The 5-year median for EBITDA is -$4.8 million (2023), against an average of -$4.7 million.
• Across the five-year window, EBITDA tumbled 911.17% in 2021 and soared 366.3% in 2025, its largest moves.
• Year by year, EBITDA stood at -$1.9 million in 2021, then slumped by 193.58% to -$5.6 million in 2022, then jumped by 30.75% to -$3.9 million in 2023, then surged by 55.71% to -$1.7 million in 2024, then surged by 366.3% to $4.6 million in 2025.
• Per Business Quant, the three latest BFRI EBITDA figures stand at $4.6 million (Q4 2025), -$6.3 million (Q3 2025), and -$5.1 million (Q2 2025).